China Isotope & Radiation Corporation Secures NMPA License for Innovative Radiotherapy System
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced that it has received a...
Product approvals
Boston Scientific’s FARAPULSE Pulse Field Ablation System Earns NMPA Approval
Boston Scientific Corporation (NYSE: BSX), a leading medical device company in the U.S., has announced...
Ascentage Pharma’s Olverembatinib Receives Marketing Approval from Macau SAR for CML Treatment
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...
Allist Pharmaceuticals Receives NMPA Approval for Phase III Trial of Furmonertinib in EGFR Mutated NSCLC
Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received approval...
Yantai Dongcheng Pharmaceutical Gets NMPA Approval for ⁹⁹ᵐTc Tetrofosmin Imaging Agent
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...
Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...
Roche’s Alecensa Secures NMPA Approval as Adjuvant Therapy for Early-Stage NSCLC
Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional...
Novo Nordisk’s Esperoct Receives NMPA Approval, First Long-Acting Factor VIII for Hemophilia A in China
The National Medical Products Administration (NMPA) has granted approval to Novo Nordisk (NYSE: NVO), a...
PharmaEssentia’s Besremi Receives Approval for Polycythemia Vera Treatment in China
PharmaEssentia Corporation (TPE: 6446, FRA: 8Z1), a biopharmaceutical company based in Taiwan, has announced that...
Haisco Pharmaceutical’s Crisugabalin Gains NMPA Approval for Post-Herpes Neuralgia Treatment
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a leading pharmaceutical company based in China, has...
Easton Pharmaceutical Receives NMPA Approval for Generic Oxcarbazepine
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain
Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...
Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management
Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...
J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients
Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...
Blue Sail Medical’s Fastroad Catheter Earns NMPA Marketing Approval
Blue Sail Medical Co., Ltd (SHE: 002382), a medical device company based in China, has...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru
MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...
Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...